Neoadjuvant Chemoimmunotherapy Complicates Subsequent Surgical Resection and Adjuvant Immunotherapy Is Preferable From the Surgical Standpoint.
(2024) Journal of Thoracic Oncology — Vol. 19, n° 6, p. 858-861 (2024)
Files
2024_Ugalde_Figueroa_J_Thorac_Oncol.pdf
Open Access - Adobe PDF
- 177.53 KB
Details
- Authors
- Abstract
- In April 2022, Forde et al.1 published the CheckMate 816 trial, the first ever phase 3 trial reporting that neoadjuvant chemotherapy plus nivolumab followed by surgery offered superior pathologic complete response and event-free survival as compared with neoadjuvant chemotherapy followed by surgery in patients with clinical-stage IB to IIIA NSCLC staged using the seventh edition TNM classifications.1 Favorable oncologic outcomes have since been reported from several additional phase 3 trials of neoadjuvant chemoimmunotherapy using immune checkpoint inhibitors (ICIs) followed by surgery in patients with resectable NSCLC.2–4 As a result, the treatment of patients with locally advanced NSCLC is dramatically changing. Although questions regarding toxicity, surgical technical challenges, and a potential increase in perioperative surgical complications have been raised, international guidelines now recommend neoadjuvant chemoimmunotherapy followed by surgery as the standard of care. As surgeons, it is incumbent on us to evaluate the impact of neoadjuvant chemoimmunotherapy with ICIs on surgical outcomes to inform patient selection criteria, particularly in patients without N2 lymph node (LN) involvement.[...]
- Affiliations
Citations
Ugalde Figueroa, P., Lacroix, V., & Van Schil, P. E. (2024). Neoadjuvant Chemoimmunotherapy Complicates Subsequent Surgical Resection and Adjuvant Immunotherapy Is Preferable From the Surgical Standpoint. Journal of Thoracic Oncology, 19(6), 858-861. https://doi.org/10.1016/j.jtho.2024.02.009 (Original work published 2024)